Mia Wibowo

Biochemistry, Genetics and Molecular Biology · Life Sciences

8h-index354citations32works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(18), CRISPR and Genetic Engineering(15), RNA Interference and Gene Delivery(10), CAR-T cell therapy research(10), Glioma Diagnosis and Treatment(8)

Publications32 total

Supplementary Figure Legends from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 7 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 1 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 5 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Methods from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Data from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 5 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 6 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 3 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 1 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Data from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Methods from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 2 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 2 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 6 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 4 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure Legends from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 7 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 4 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
Supplementary Figure 3 from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Pedro R. Löwenstein(31), María G. Castro(31), Kader Yagiz(26), Mariana Puntel(26), Gabrielle E. Ahlzadeh(22), Homayon Ghiasi(21), Neha Kamran(21), Christopher Paran(21), Marianela Candolfi(18), Marianela Candolfi(9), Kurt M. Kroeger(8), Hikmat Assi(6), Chunyan Liu(5), James F. Curtin(4), David Foulad(4), Niyati Bondale(4), A.K.M. Ghulam Muhammad(3), Gregory J. Baker(3), Robert R. Dunn(2), Yohei Mineharu(2)